» Articles » PMID: 31914002

Characterizing Viral Load Burden Among HIV-Infected Women Around the Time of Delivery: Findings From Four Tertiary Obstetric Units in Gauteng, South Africa

Overview
Date 2020 Jan 9
PMID 31914002
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Elimination of mother-to-child transmission of HIV requires sustained viral load suppression during pregnancy and breastfeeding among women living with HIV (WLHIV). Antenatal antiretroviral therapy coverage is reported at >95% in South Africa, but viral load suppression rates are unknown. We describe maternal VL burden around time of delivery at 4 tertiary obstetric units (TOUs) in Gauteng Province.

Methods: Between June 2018 and March 2019, routine point-of-care (PoC) maternal HIV VL and early infant diagnosis (EID) testing were implemented at 3 TOUs in Johannesburg and 1 in Tshwane district. WLHIV and HIV-exposed neonates were eligible for HIV VL (Xpert HIV-1 VL) and EID (Xpert HIV-1 EID or m-PIMA HIV1/2 detection) testing around time of delivery, respectively. Proportions of viremic women and intrauterine (IU)-infected neonates were calculated among valid PoC results.

Results: Among 8147 live births to WLHIV, 2769 (34.0%) women and 4333 (53.2%) neonates had valid PoC results. Median VL at delivery was <40 copies/mL (interquartile range: 0-398). The proportion of women with a VL < 50, 50 to <1000, and ≥1000 copies/mL was 63.6%, 13.9% and 22.4%, respectively. There were 65/4333 (1.5%) IU-infected neonates. Among 1449 mother-neonate pairs with both VL and EID results, IU transmission by VL threshold was 3/946 (0.3%), 6/187 (3.2%), and 25/316 (7.9%) for VL < 50, 50 to <1000, and ≥1000 copies/mL, respectively (P < 0.001).

Conclusions: Despite high antiretroviral therapy coverage, >1/3 of WLHIV had a VL ≥50 copies/mL at delivery. Among mother-neonate pairs, maternal VL ≥50 copies/mL accounted for 31/34 (91%) IU infections. Improvement in the quality of HIV care among WLHIV is essential if South Africa is to achieve elimination of mother-to-child transmission.

Citing Articles

Human Immunodeficiency Virus (HIV) viral load suppression status and associated factors among pregnant women receiving Highly Active Antiretroviral Therapy (HAART) in Ethiopia.

Hailu G, Keraleme A, Zealiyas K, Tesema A, Nuramed N, Girmachew F Virol J. 2025; 22(1):49.

PMID: 40001227 PMC: 11853537. DOI: 10.1186/s12985-025-02659-0.


Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1.

Cunningham C, McFarland E, Muresan P, Capparelli E, Perlowski C, Johnston B J Pediatric Infect Dis Soc. 2025; 14(2).

PMID: 39821046 PMC: 11799610. DOI: 10.1093/jpids/piaf002.


Feasibility and staff acceptability of implementing Xpert HIV-1 viral load point-of-care testing: a pilot study in San Francisco.

Moore Jr K, Le Tourneau N, Alvarez J, Rodriguez S, Broussard J, Crouch P BMC Infect Dis. 2025; 25(1):26.

PMID: 39762731 PMC: 11702105. DOI: 10.1186/s12879-024-10384-2.


The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.

Broyles L, Luo R, Boeras D, Vojnov L Lancet. 2023; 402(10400):464-471.

PMID: 37490935 PMC: 10415671. DOI: 10.1016/S0140-6736(23)00877-2.


HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study.

Breton G, Cisse M, Diallo O, Diallo N, Soumaoro S, Camara Y J Antimicrob Chemother. 2022; 77(11):3093-3101.

PMID: 36031792 PMC: 9616546. DOI: 10.1093/jac/dkac287.